News >

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

Angelica Welch
Published: Tuesday, Nov 21, 2017

What I would say to oncologists in the community would be to try to get your patients into a clinical trial so that they can be studied in an environment where they can gain information as they gain benefit from the treatment. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication